Form 4: Seres Therapeutics Director Richard N. Kender Acquires Stock Options

Director Richard N. Kender acquired stock options for 100,000 shares of Seres Therapeutics, Inc. at an exercise price of $0.58 on April 10, 2025.

Summary

• On April 10, 2025, Richard N. Kender, a director of Seres Therapeutics, Inc., acquired stock options for 100,000 shares.
• The exercise price of these options is $0.58 per share.
• The options vest fully on the earlier of April 10, 2026, or the day before the company's 2026 annual meeting of shareholders.
• The options expire on April 9, 2035.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• Shareholders may view this as a positive sign if they believe the director's stock option acquisition reflects confidence in the company's future prospects.

Key Dates

Keywords

Seres Therapeutics, Director, Stock Options, Acquisition, MCRB, Richard N. Kender